Table 1.
Baseline demographics of included studies
| Year of publication | First author | Condition being treated | Agent | Treatment regimen | Baseline number of eyes | Age (mean±SD) | Initial BCVA in ETDRS letters (mean±SD) | Initial retinal thickness (mean±SD) |
| 2021 | Holz23 | nAMD | RAN | Monthly | 239 | 50–94* | N/A | N/A |
| FYB201 | Monthly | 238 | 50–91* | N/A | N/A | |||
| 2021 | Bressler24 | nAMD | RAN | Monthly | 354 | 74(9) | 58 (10.8)† | 412 (121.3)† |
| SB11 | Monthly | 351 | 74(8) | 59 (10.4)† | 404 (113.8)† | |||
| 2021 | Apsangikar26 | nAMD | RAN | Monthly | 53 | 67 | N/A | 316 (120.8) |
| Biosimilar Ranibizumab (RanizuRelTM) | Monthly | 107 | 67 | N/A | 324 (103.2) | |||
| 2022 | Singh27 | nAMD | RAN | Monthly | 101 | 67(11) | N/A | N/A |
| Lupin’s Ranibizumab Biosimilar (LUBT010) |
Monthly | 101 | 67(10) | N/A | N/A |
*Range.
†Retrieved from Woo 2021.
BCVA, best corrected visual acuity; DGCI, Drugs Controller General of India; ETDRS, early treatment diabetic retinopathy study; N/A, not available; RAN, ranibizumab.